Canada markets open in 8 hours 45 minutes

NextCure, Inc. (NXTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.8800-0.1200 (-2.40%)
At close: 04:00PM EDT
4.8800 0.00 (0.00%)
After hours: 04:02PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • L
    $GALT conversation
    $NXTC is up +65.79 (+248.92%) today. $GALT can make similar, sudden upward moves. $NXTC has a drug that targets Siglec-15 (S15). Siglecs and Galectins are both types of lectins, except $GALT is much further along in development.
  • a
    why is this company valued high without strong pipelines?
  • C
    I was going to short this thing since it had that big run-up but my broker told me a few things that changed my opinion on it.
    The news that it soared up on is not much changed in this last report and as of yesterday and today Piper Jaffray Companies has reiterated it's positive Overweight rating and it's $95 target.
    And Bank of America today reiterated it's Buy rating and has an $89 target. It had a $27 target in Sept.
    If anything I'm buying here. Thoughts?
  • D
    NextCure announced the initiation of the Phase 2 portion of its ongoing Phase 1/2 clinical trial of NC318. With ongoing trials and early stage results I find it hard to value this at current prices
  • G
    Grandpa Platt
    This is another company with a wide price target range, $11-$55. Win big or break even. Sounds like a good deal to me.
  • J
  • s
    Didn't think this was going to crash today. Loaded up big time yesterday thinking the bottom had been reached. Obviously i was wrong ....
  • M
    CEO running from HQ this morning
  • E
    “The stock took off like a rocket today when investors learned that one patient achieved complete remission, another experienced tumor shrinkage, and three more haven't gotten any worse”
  • K
    Buy opportunity
  • M
    Why did it pop up so much?
  • a
    best. short. ever.
  • A
    Angel Santos
    From here (74.41), i'm expecting this to hit 90 again, but others would disagree. I'm not doubting this could go down, but if anyone is at this position, stay alert. This game isn't over just yet.
  • M
    $2.6 billion market cap? this has a long way to fall.....
  • m
    Extremely under value, should be 50~100/share.
  • M
    Next Cure for Wealth!
  • E
    Data from our preclinical studies revealed that NC410 promotes T cell mediated anti-tumor immunity as well as infiltration and localized activity of T cells in the TME, suggesting its potential as a cancer monotherapy or combination therapy with checkpoint inhibitors particularly for immune-excluded, collagen-rich tumors.”
  • k
    This run based on Phase 1 data - Phase 1!!! $NXTC

    $26 on Nov. 4

    $92 on Nov. 5

    $67 on Nov. 6

    $83 on Nov. 8
  • D
    Anyone with a long term insight on fundamentals and technicalities of companies knows yday’s move was arbitrary and can’t be used to make long term investment decisions. I personally will not long NXTC at current price or even -500% current price. Reason? They have a Siglec-15 (S15) antibody called NC318 which is its only new drug candidate in clinical-stage testing.
    The only results they have presented was in March when the company told us that NC318 shrank tumors for one lung-cancer patient treated in a proof-of-concept study. According to Motley Fool, “The stock took off like a rocket today when investors learned that one patient achieved complete remission, another experienced tumor shrinkage, and three more haven't gotten any worse.”
    Guys, ever heard of a company called Theranos? It WAS a privately held health technology corporation, initially touted as a breakthrough technology company, but subsequently infamous for its false claims to have devised blood tests that only needed very small amounts of blood.
    Caveat Emptor before jumping into this!!!
  • C
    $283M cash, almost no debt, some catalysts will come late this year and earlier next year, I think NXTC is a buy now. The pipeline is like free at this level.